Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer

Olivotto, Ivo A.; Bajdik, Chris; Ravdin, Peter M.; Speers, Caroline; Coldman, Andrew J.; Norris, B.; Davis, Greg; Chia, Stephen; Gelmon, Karen A.

doi:10.1200/jco.2005.06.178

Cited by 493 publications

(326 citation statements)

References 19 publications

Supporting

Mentioning

306

Contrasting

Unclassified

Order By: Relevance

“…Therefore, we compared the signature to clinicopathological risk assessment, by Adjuvant! [11,12]. As anticipated, Adjuvant!…”

Section: Discussionsupporting

confidence: 52%

“…The Adjuvant! software version 8.0-available at www.adjuvantonline.com-calculated 10-year survival probability based on patient's age, co-morbidities, tumour size, tumour grade, ER-status and number of positive axilllary lymph nodes [11,12]. Patients were considered as having low clinical risk when the 10-year BCSS as predicted by Adjuvant!…”

Section: Clinicopathological Datamentioning

confidence: 99%

See 1 more Smart Citation

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study

Mook

Schmidt

Viale

et al. 2008

Breast Cancer Res Treat

261

152

View full text Add to dashboard Cite

“…Therefore, we compared the signature to clinicopathological risk assessment, by Adjuvant! [11,12]. As anticipated, Adjuvant!…”

Section: Discussionsupporting

confidence: 52%

Section: Clinicopathological Datamentioning

confidence: 99%

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study

Mook

Schmidt

Viale

et al. 2008

Breast Cancer Res Treat

261

152

View full text Add to dashboard Cite

“…Clinicopathological risk indexes included: St Gallen guidelines [24][25][26][27][28], Nottingham Prognostic Index [29][30][31], Dutch CBO guidelines 2004-available at www.oncoline.nl- [32,33] and Adjuvant! Online-available at www.adjuvantonline.com [34][35][36]. In this study, a moderate or high clinical risk was an indication for adjuvant systemic treatment.…”

Section: Established Clinical Risk Classifications Indexesmentioning

confidence: 99%

“…Online Software calculates a 10-year survival probability based on the patient's age, tumour size, histological tumour grade, oestrogen receptor status and nodal status [34][35][36]. A low clinical risk was defined as patients with a 10-years survival probability of at least 90%.…”

Section: Established Clinical Risk Classifications Indexesmentioning

confidence: 99%

Validation of 70-gene prognosis signature in node-negative breast cancer

Bueno-de-Mesquita

Linn

Keijzer

et al. 2008

Breast Cancer Res Treat

149

View full text Add to dashboard Cite

International audienceThe 70-gene prognosis signature (van't Veer et al., Nature 415(6871):530–536, 2002) may improve the selection of lymph node-negative breast cancer patients for adjuvant systemic therapy. Optimal validation of prognostic classifiers is of great importance and we therefore wished to evaluate the prognostic value of the 70-gene prognosis signature in a series of relatively recently diagnosed lymph node negative breast cancer patients. We evaluated the 70-gene prognosis signature in an independent representative series of patients with invasive breast cancer ( = 123; <55 years; pT1-2N0; diagnosed between 1996 and 1999; median follow-up 5.8 years) by classifying these patients as having a good or poor prognosis signature. In addition, we updated the follow-up of the node-negative patients of the previously published validation-series (Van de Vijver et al., N Engl J Med 347(25):1999–2009, 2002; = 151; median follow-up 10.2 years). The prognostic value of the 70-gene prognosis signature was compared with that of four commonly used clinicopathological risk indexes. The endpoints were distant metastasis (as first event) free percentage (DMFP) and overall survival (OS). The 5-year OS was 82 ± 5% in poor (48%) and 97 ± 2% in good prognosis signature (52%) patients (HR 3.4; 95% CI 1.2–9.6; = 0.021). The 5-years DMFP was 78 ± 6% in poor and 98 ± 2% in good prognosis signature patients (HR 5.7; 95% CI 1.6–20; = 0.007). In the updated series ( = 151; 60% poor vs. 40% good), the 10-year OS was 51 ± 5% and 94 ± 3% (HR 10.7; 95% CI 3.9–30; < 0.01), respectively. The DMFP was 50 ± 6% in poor and 86 ± 5% in good prognosis signature patients (HR 5.5; 95% CI 2.5–12; < 0.01). In multivariate analysis, the prognosis signature was a strong independent prognostic factor in both series, outperforming the clinicopathological risk indexes. The 70-gene prognosis signature is also an independent prognostic factor in node-negative breast cancer patients for women diagnosed in recent years

show abstract

“…Los resultados calculados por el Adjuvant! (esperados) y observados a 10 años en SG, SEE y SLE difieren globalmente en sólo 1% 20 .…”

Section: Discussionunclassified

Evaluación de un modelo computacional para la indicación de quimioterapia en cáncer de mama

Galindo

et al. 2007

Rev Chil Cir

View full text Add to dashboard Cite

Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer

Abstract: Adjuvant! performed reliably. Patients younger than age 35 or with known additional adverse prognostic factors such as LVI require adjustment of risks to derive reliable predictions of prognosis without adjuvant systemic therapy and the absolute benefits of adjuvant systemic therapy.

Cited by 493 publications

References 19 publications

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study

Validation of 70-gene prognosis signature in node-negative breast cancer

Evaluación de un modelo computacional para la indicación de quimioterapia en cáncer de mama

Contact Info

Product

Resources

About